ReviewFrontiers in cell and developmental biology2026
The relationship between sarcopenia and breast cancer: mechanistic pathways and clinical relevance.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the most frequently diagnosed malignancy among women worldwide and one of the leading causes of cancer-related mortality. Despite advances in screening and therapeutic strategies, its prevention and treatment continue to face considerable challenges due to pronounced tumor heterogeneity, therapeutic resistance, and treatment-related toxicities. Sarcopenia, a syndrome characterized by progressive loss of skeletal muscle mass (SMM) and function, is increasingly prevalent in patients with breast cancer and has been consistently associated with adverse clinical outcomes. In this review, we systematically summarize epidemiological evidence linking sarcopenia to breast cancer and elucidate its association with increased postoperative complications, heightened toxicity from systemic therapies, and inferior survival outcomes. We further explore potential pathophysiological mechanisms underlying this association, including altered pharmacokinetics that may contribute to exacerbated drug toxicity, dysregulated myokine signaling, and chronic inflammation that is linked to tumor progression, insulin resistance, and detrimental changes in physical function and health behaviors. In addition, current evidence regarding strategies for the identification and management of sarcopenia-encompassing diagnostic assessments, pharmacological interventions, nutritional support, and exercise training-is critically evaluated. By integrating current findings, this review highlights the pivotal role of sarcopenia in the development and progression of breast cancer and provides insight into multimodal intervention strategies that may improve clinical outcomes in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.